Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.
Saved in:
| Title: | Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors. |
|---|---|
| Authors: | Derbala MH; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Stephen B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hwang W; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of)., Ock CY; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of)., Hwang S; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of)., Hajjar J; Division of Immunology, Allergy and Retrovirology, Baylor College of Medicine, Houston, Texas, USA., Lee S; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of)., Zhou J; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gurses SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., McGonagle KE; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Alshawa A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Castillo L; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zarifa A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Solis Soto LM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Raso MG; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ali S; Lunit Inc, Gangnam-gu, Seoul, Korea (the Republic of)., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA anaing@mdanderson.org. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Jun 24; Vol. 14 (6). Date of Electronic Publication: 2026 Jun 24. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
